Vitamin K2 and the Modern Diet Gap: What Calcium Goes Looking For

The first thing to understand about vitamin K is that the umbrella term covers two functionally distinct compounds, and treating them as interchangeable has produced decades of misleading dietary guidance. Vitamin K1 (phylloquinone) is the form found in leafy green vegetables, where it functions in plant photosynthesis. Vitamin K2 (menaquinone) is produced primarily by bacteria, found in fermented foods and animal products, and exists in several subtypes denoted MK-4 through MK-13 based on the length of the side chain. The two forms enter different metabolic pools after absorption, distribute to different tissues, and produce different physiological effects. The 2019 Halder review in the International Journal of Molecular Sciences laid out this distinction with the kind of clarity that the popular nutrition discourse still lacks.

What Each Form Actually Does

K1 is taken up primarily by the liver and used to activate the coagulation factors that prevent bleeding disorders. The dietary requirement for adequate coagulation function is met by typical Western diets through leafy green consumption. Frank K1 deficiency is rare in adults outside of malabsorption conditions and certain medications.

K2 is taken up by extrahepatic tissues — bone, vascular wall, kidney — and used to activate matrix Gla-protein and osteocalcin. The functional consequences are specific. Activated matrix Gla-protein inhibits calcium deposition in arterial walls. Activated osteocalcin binds calcium to bone matrix. Inadequate K2 leads to a paradoxical state in which calcium deposits where it should not (arteries) and fails to deposit where it should (bone). The condition is called the “calcium paradox” in the cardiovascular literature, and it explains why high calcium intake without adequate K2 can simultaneously increase cardiovascular risk and fail to improve bone density in some populations.

The Rotterdam Study Finding

Geleijnse and colleagues, in the Rotterdam Study published in 2004, examined the relationship between dietary K2 intake and coronary heart disease in 4,807 adults followed for nearly 8 years. The findings were striking. Participants in the highest tertile of K2 intake had a 57% lower risk of coronary heart disease mortality compared to those in the lowest tertile. The association held after adjusting for traditional cardiovascular risk factors including age, smoking, blood pressure, lipid profile, and diabetes status.

K1 intake in the same cohort showed no significant association with coronary outcomes. The protective effect was specific to the K2 form. Beulens and colleagues (2009) extended this finding using direct measurement of coronary calcification, demonstrating that higher K2 intake was associated with lower calcification scores while K1 intake again showed no relationship. The mechanistic story — K2 activating matrix Gla-protein to prevent vascular calcification — matched the epidemiological pattern.

The Bone Density Evidence

Knapen and colleagues (2013) conducted a 3-year randomized controlled trial of low-dose MK-7 (180 micrograms daily) in 244 healthy postmenopausal women. The intervention group showed statistically significant preservation of lumbar spine bone mineral density compared to placebo, and the magnitude of the effect was clinically meaningful. The MK-7 group also showed improved bone strength markers and reduced age-related decline in vertebral height.

The dose used in this trial — 180 micrograms — is roughly an order of magnitude higher than typical dietary K2 intake in Western populations. NIH data on K vitamin intake suggests most adults consume less than 30 micrograms of K2 daily, and a substantial fraction consume essentially none if they avoid fermented foods, organ meats, and high-fat dairy.

The Diet Gap

The reason K2 intake is low in modern Western diets is structural. K2 sources are concentrated in foods that have been deliberately reduced or eliminated by population-level dietary guidance over the past several decades. Natto (Japanese fermented soybean) is by far the richest dietary source of MK-7 but is essentially absent from non-East-Asian diets. Hard cheeses produced through bacterial fermentation contain meaningful MK-9. Egg yolks, organ meats, and full-fat dairy from grass-fed animals contain MK-4. Each of these foods has been targeted by either fat-reduction guidance or simple cultural shift.

The Korean diet historically contains substantial K2 from fermented foods including doenjang, gochujang, and various traditional cheonggukjang preparations. Modern Korean dietary patterns have partially preserved this advantage compared to Western patterns, though processed food substitution has eroded it over recent decades.

What Adequate Intake Might Look Like

The NIH adequate intake recommendation for total vitamin K is 90 micrograms daily for women and 120 micrograms for men, but this guideline does not distinguish between K1 and K2. Population intake data suggests most adults meet the K1 portion through vegetable consumption but fall well short of intakes associated with the cardiovascular and bone protective effects observed for K2.

The clinical literature does not yet support a precise daily K2 target, but the trial evidence supports intakes substantially higher than typical Western consumption. The MK-7 form is preferred for supplementation because of its longer half-life — circulating MK-7 remains biologically active for roughly 72 hours, compared to under 8 hours for MK-4. A 100-200 microgram daily MK-7 dose, which is the range used in most positive trials, is widely available in supplement form.

For dietary intervention rather than supplementation, the practical sources are narrow. Natto delivers approximately 1000 micrograms of MK-7 per 100-gram serving. Hard fermented cheeses (gouda, edam, brie) provide 50-90 micrograms per 100 grams. Pasture-raised egg yolks and full-fat dairy contribute smaller but meaningful amounts. The dietary intervention requires deliberate inclusion of foods that mainstream nutrition guidance has often discouraged for unrelated reasons.

The Synthesis

The K2 story illustrates one of the more consistent failures of population-level nutrition guidance. The deficiency is real, the consequences are clinically meaningful, the dietary sources are identifiable, and the supplementation evidence is reasonably solid. The barrier to adequate intake is not scientific uncertainty but the gap between what the research supports and what dietary recommendations communicate. For individuals concerned about cardiovascular and bone health, particularly those with osteopenia, family history of cardiovascular disease, or low intake of fermented foods, K2 deserves attention that population-level guidance does not yet give it.